Fat Graft Enhanced With Adipose-Derived Stem Cells in Aesthetic Breast Augmentation: Clinical, Histological, and Instrumental Evaluation
Fat Graft Enhanced With Adipose-Derived Stem Cells in Aesthetic Breast Augmentation: Clinical, Histological, and Instrumental Evaluation
复制标题
DOI：
10.1093/asj/sjz292
复制
发表时间：
2020-09-01
影响因子：
2.9
通讯作者：
Calabrese, Claudio
中科院分区：
文献类型：
--
作者：
Gentile, Pietro;Kothari, Ashutosh;Calabrese, Claudio
背景资料：脂肪干细胞增强的脂肪移植物（FG-e-ASCs）已被用于乳腺切除术后放疗、乳房软组织缺损、溃疡和物质损失的结局。目的：本研究的目的是评价研究组（SG）在隆乳术中使用FG-e-ASCs改善美观方面的安全性和有效性，并将结果与对照组（CG）进行比较。方法：共有46名乳腺发育不良患者接受了FG-e-ASC治疗，将结果与用未经脂肪来源的干细胞（FG-ne-ASC）增强的脂肪移植物处理的CG（n = 30）的结果进行比较。术前评价包括完整的临床评价、摄影评估、软组织磁共振成像、超声和乳腺X线摄影。术后随访时间分别为1、3、7、12、24、48周，之后每年随访一次。结果：3年后，FG-e-ASCs治疗组的轮廓恢复和三维体积维持率为58%，而FG-ne-ASCs治疗组的轮廓恢复和三维体积维持率为29%。在67.4%（n = 31）接受FG-e-ASC治疗的隆乳患者中，我们观察到36个月后乳房轮廓恢复，3D体积增加10.3 mm，而在接受FG-ne-ASC治疗的CG患者中仅观察到20.0%（n = 6）。SG组的容积持续性高于CG组（P < 0.0001）。结论：在本系列病例中使用FG-e-ASCs是安全有效的。
Background: Fat graft enhanced with adipose-derived stem cells (FG-e-ASCs) has been utilized in outcomes of radiotherapy after mastectomy, breast soft tissue defects, ulcers, and loss of substance. The authors present their experience utilizing FG-e-ASCs in breast augmentation.Objectives: The aim of this study was to evaluate the safety and efficacy of a study group (SG) regarding utilization of FG-e-ASCs in breast augmentation for aesthetic improvement, comparing the results with a control group (CG).Methods: A total of 46 patients affected by breast hypoplasia were treated with FG-e-ASCs, comparing results with those of a CG (n = 30) treated with fat graft not enhanced with adipose-derived stem cells (FG-ne-ASCs). The preoperative evaluation included a complete clinical evaluation, a photographic assessment, magnetic resonance imaging of the soft tissue, ultrasound, and mammography. Postoperative follow-up took place at 1, 3, 7, 12, 24, and 48 weeks and then annually.Results: The patients treated with FG-e-ASCs showed 58% maintenance of the contour restoring and of 3-dimensional (3D) volume after 3 years compared with the patients of the CG treated with FG-ne-ASCs, who showed 29% maintenance. In 67.4% (n = 31) of breast augmentations treated with FG-e-ASCs, we observed a restoration of the breast contour and an increase of 10.3 mm in the 3D volume after 36 months, which was observed in only 20.0% (n = 6) of patients in the CG treated with FG-ne-ASCs. Volumetric persistence in the SG was higher than that in the CG (P < 0.0001 SG vs CG).Conclusions: Utilization of FG-e-ASCs was safe and effective in this series of cases performed.